Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics

Lexicon Pharmaceuticals, Inc. (LXRX): $2.40

0.21 (+9.59%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Add LXRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#342 of 365

in industry

LXRX Price/Volume Stats

Current price $2.40 52-week high $3.79
Prev. close $2.19 52-week low $0.92
Day low $2.13 Volume 7,061,100
Day high $2.47 Avg. volume 4,877,666
50-day MA $2.30 Dividend yield N/A
200-day MA $1.73 Market Cap 590.97M

LXRX Stock Price Chart Interactive Chart >

LXRX POWR Grades

  • LXRX scores best on the Growth dimension, with a Growth rank ahead of 15.93% of US stocks.
  • LXRX's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
  • LXRX's current lowest rank is in the Quality metric (where it is better than 3.47% of US stocks).

LXRX Stock Summary

  • With a price/sales ratio of 696.49, LEXICON PHARMACEUTICALS INC has a higher such ratio than 99.18% of stocks in our set.
  • With a year-over-year growth in debt of 340.25%, LEXICON PHARMACEUTICALS INC's debt growth rate surpasses 97.22% of about US stocks.
  • As for revenue growth, note that LXRX's revenue has grown 324.8% over the past 12 months; that beats the revenue growth of 98.29% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to LEXICON PHARMACEUTICALS INC are DZSI, APPN, TTNP, TBIO, and FEMY.
  • Visit LXRX's SEC page to see the company's official filings. To visit the company's web site, go to www.lexpharma.com.

LXRX Valuation Summary

  • LXRX's price/sales ratio is 705.6; this is 16700% higher than that of the median Healthcare stock.
  • Over the past 243 months, LXRX's EV/EBIT ratio has gone up 1.8.

Below are key valuation metrics over time for LXRX.

Stock Date P/S P/B P/E EV/EBIT
LXRX 2023-12-29 705.6 2.7 -2.4 -3.1
LXRX 2023-12-28 705.6 2.7 -2.4 -3.1
LXRX 2023-12-27 673.4 2.6 -2.3 -3.0
LXRX 2023-12-26 650.3 2.5 -2.2 -2.9
LXRX 2023-12-22 604.3 2.3 -2.0 -2.7
LXRX 2023-12-21 585.9 2.2 -2.0 -2.6

LXRX Growth Metrics

    Its 3 year revenue growth rate is now at -99.35%.
  • Its 5 year net cashflow from operations growth rate is now at 153.99%.
  • The year over year cash and equivalents growth rate now stands at -39.05%.
LXRX's revenue has moved down $321,948,000 over the prior 33 months.

The table below shows LXRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.125 -90.11 -97.061
2022-06-30 0.109 -87.821 -96.796
2022-03-31 0.308 -85.279 -90.276
2021-12-31 0.298 -87.017 -87.758
2021-09-30 0.483 -98.428 -67.642
2021-06-30 7.094 -121.656 38.083

LXRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LXRX has a Quality Grade of D, ranking ahead of 14.8% of graded US stocks.
  • LXRX's asset turnover comes in at 0.038 -- ranking 340th of 681 Pharmaceutical Products stocks.
  • SEEL, AVEO, and OTLK are the stocks whose asset turnover ratios are most correlated with LXRX.

The table below shows LXRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.038 0.911 2.792
2021-03-31 0.071 0.915 -0.037
2020-12-31 0.089 0.920 -0.233
2020-09-30 0.101 0.917 -0.269
2020-06-30 0.824 0.992 0.131
2020-03-31 0.875 0.990 0.239

LXRX Price Target

For more insight on analysts targets of LXRX, see our LXRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.67 (Moderate Buy)

Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio


Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.


LXRX Latest News Stream


Event/Time News Detail
Loading, please wait...

LXRX Latest Social Stream


Loading social stream, please wait...

View Full LXRX Social Stream

Latest LXRX News From Around the Web

Below are the latest news stories about LEXICON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LXRX as an investment opportunity.

3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.

Yahoo | December 26, 2023

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024. Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation at 10:30am PT / 1:30 pm ET on Thursday, January 11th. Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, an

Yahoo | December 21, 2023

MSCLF: AAK1 Disclosed as Drug Target for DMD Program…

By David Bautz, PhD OTC:MSCLF READ THE FULL MSCLF RESEARCH REPORT Business Update AAK1 Disclosed as Drug Target for DMD Program On November 14, 2023, Satellos Biosciences Inc. (OTC:MSCLF) announced that AAK1 is the drug target for the company’s Duchenne muscular dystrophy (DMD) program, that SAT-3247 has been nominated as the lead drug candidate, and that IND-enabling studies and GMP

Yahoo | December 13, 2023

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in more than 20 years LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP THE WOODLANDS, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has enrolled the first patient in PROGRE

Yahoo | November 30, 2023

Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023: 35th Annual Piper Sandler Healthcare Conference6th Annual Evercore ISI HealthCONx Conference Lonnel Coats, Lexicon’s chief executive officer, Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Cr

Yahoo | November 22, 2023

Read More 'LXRX' Stories Here

LXRX Price Returns

1-mo -8.40%
3-mo 56.86%
6-mo 120.18%
1-year 1.27%
3-year -58.69%
5-year -56.83%
YTD 56.86%
2023 -19.90%
2022 -51.52%
2021 15.20%
2020 -17.59%
2019 -37.50%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!